These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 31217340)

  • 1. A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer.
    Crawford A; Haber L; Kelly MP; Vazzana K; Canova L; Ram P; Pawashe A; Finney J; Jalal S; Chiu D; Colleton CA; Garnova E; Makonnen S; Hickey C; Krueger P; DelFino F; Potocky T; Kuhnert J; Godin S; Retter MW; Duramad P; MacDonald D; Olson WC; Fairhurst J; Huang T; Martin J; Lin JC; Smith E; Thurston G; Kirshner JR
    Sci Transl Med; 2019 Jun; 11(497):. PubMed ID: 31217340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition.
    Yeku OO; Rao TD; Laster I; Kononenko A; Purdon TJ; Wang P; Cui Z; Liu H; Brentjens RJ; Spriggs D
    Front Immunol; 2021; 12():663379. PubMed ID: 33936101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes.
    Belisle JA; Horibata S; Jennifer GA; Petrie S; Kapur A; André S; Gabius HJ; Rancourt C; Connor J; Paulson JC; Patankar MS
    Mol Cancer; 2010 May; 9():118. PubMed ID: 20497550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors.
    Ishiguro T; Sano Y; Komatsu SI; Kamata-Sakurai M; Kaneko A; Kinoshita Y; Shiraiwa H; Azuma Y; Tsunenari T; Kayukawa Y; Sonobe Y; Ono N; Sakata K; Fujii T; Miyazaki Y; Noguchi M; Endo M; Harada A; Frings W; Fujii E; Nanba E; Narita A; Sakamoto A; Wakabayashi T; Konishi H; Segawa H; Igawa T; Tsushima T; Mutoh H; Nishito Y; Takahashi M; Stewart L; ElGabry E; Kawabe Y; Ishigai M; Chiba S; Aoki M; Hattori K; Nezu J
    Sci Transl Med; 2017 Oct; 9(410):. PubMed ID: 28978751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer.
    Wang Q; Ma X; Wu H; Zhao C; Chen J; Li R; Yan S; Li Y; Zhang Q; Song K; Yuan C; Kong B
    Oncoimmunology; 2022; 11(1):2096362. PubMed ID: 35800156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MUC16 suppresses human and murine innate immune responses.
    Felder M; Kapur A; Rakhmilevich AL; Qu X; Sondel PM; Gillies SD; Connor J; Patankar MS
    Gynecol Oncol; 2019 Mar; 152(3):618-628. PubMed ID: 30626487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3.
    Garg G; Gibbs J; Belt B; Powell MA; Mutch DG; Goedegebuure P; Collins L; Piwnica-Worms D; Hawkins WG; Spitzer D
    BMC Cancer; 2014 Jan; 14():35. PubMed ID: 24447304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies.
    Stasenko M; Smith E; Yeku O; Park KJ; Laster I; Lee K; Walderich S; Spriggs E; Rueda B; Weigelt B; Zamarin D; Rao TD; Spriggs DR
    Sci Rep; 2021 Feb; 11(1):3718. PubMed ID: 33580170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells.
    Gubbels JA; Felder M; Horibata S; Belisle JA; Kapur A; Holden H; Petrie S; Migneault M; Rancourt C; Connor JP; Patankar MS
    Mol Cancer; 2010 Jan; 9():11. PubMed ID: 20089172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies.
    Skokos D; Waite JC; Haber L; Crawford A; Hermann A; Ullman E; Slim R; Godin S; Ajithdoss D; Ye X; Wang B; Wu Q; Ramos I; Pawashe A; Canova L; Vazzana K; Ram P; Herlihy E; Ahmed H; Oswald E; Golubov J; Poon P; Havel L; Chiu D; Lazo M; Provoncha K; Yu K; Kim J; Warsaw JJ; Stokes Oristian N; Siao CJ; Dudgeon D; Huang T; Potocky T; Martin J; MacDonald D; Oyejide A; Rafique A; Poueymirou W; Kirshner JR; Smith E; Olson W; Lin J; Thurston G; Sleeman MA; Murphy AJ; Yancopoulos GD
    Sci Transl Med; 2020 Jan; 12(525):. PubMed ID: 31915305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.
    Bühler P; Wolf P; Gierschner D; Schaber I; Katzenwadel A; Schultze-Seemann W; Wetterauer U; Tacke M; Swamy M; Schamel WW; Elsässer-Beile U
    Cancer Immunol Immunother; 2008 Jan; 57(1):43-52. PubMed ID: 17579857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.
    Gubbels JA; Belisle J; Onda M; Rancourt C; Migneault M; Ho M; Bera TK; Connor J; Sathyanarayana BK; Lee B; Pastan I; Patankar MS
    Mol Cancer; 2006 Oct; 5(1):50. PubMed ID: 17067392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy in a human ovarian cancer xenograft model with two bispecific monoclonal antibodies: OV-TL 3/CD3 and OC/TR.
    van Ravenswaay Claasen HH; Eggermont AM; Nooyen YA; Warnaar SO; Fieuren GJ
    Gynecol Oncol; 1994 Feb; 52(2):199-206. PubMed ID: 8314139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo.
    English DP; Bellone S; Schwab CL; Roque DM; Lopez S; Bortolomai I; Cocco E; Bonazzoli E; Chatterjee S; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
    Cancer; 2015 Feb; 121(3):403-12. PubMed ID: 25251053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice.
    Li T; Wang J
    BMC Cancer; 2020 Jul; 20(1):678. PubMed ID: 32689954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Membrane-type I matrix metalloproteinase-dependent ectodomain shedding of mucin16/ CA-125 on ovarian cancer cells modulates adhesion and invasion of peritoneal mesothelium.
    Bruney L; Conley KC; Moss NM; Liu Y; Stack MS
    Biol Chem; 2014 Oct; 395(10):1221-31. PubMed ID: 25205731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical evaluation of light-activatable, bispecific anti-human CD3 antibody conjugates as anti-ovarian cancer therapeutics.
    Thompson S; Dessi J; Self CH
    MAbs; 2009; 1(4):348-56. PubMed ID: 20068406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PAX8 lineage-driven T cell engaging antibody for the treatment of high-grade serous ovarian cancer.
    Lee E; Szvetecz S; Polli R; Grauel A; Chen J; Judge J; Jaiswal S; Maeda R; Schwartz S; Voedisch B; Piksa M; Japutra C; Sadhasivam L; Wang Y; Carrion A; Isim S; Liang J; Nicholson T; Lei H; Fang Q; Steinkrauss M; Walker D; Wagner J; Cremasco V; Wang HQ; Galli GG; Granda B; Mansfield K; Simmons Q; Nguyen AA; Vincent Jordan N
    Sci Rep; 2021 Jul; 11(1):14841. PubMed ID: 34290299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with B7H3-redirected bispecific antibody and Sorafenib elicits enhanced synergistic antitumor efficacy.
    Huang C; Li H; Feng Y; Li X; Zhang Z; Jiang C; Wang J; Yang C; Fu Y; Mu M; Zhao S; Wang Z; Kuang Y; Hou H; Wang Y; Guo W; Xu J; Yang H; Zhou L; Tong A; Guo G
    Theranostics; 2020; 10(23):10498-10512. PubMed ID: 32929362
    [No Abstract]   [Full Text] [Related]  

  • 20. [MUC16: The Novel Target for Tumor Therapy].
    Gao R; Lou N; Han X; Shi Y
    Zhongguo Fei Ai Za Zhi; 2022 Jul; 25(7):452-459. PubMed ID: 35899441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.